A Comparative Study to Evaluate the Evolution of Medication Satisfaction and Adherence in Patients Unsatisfied With Current Oral Atypical Antipsychotics by Switching Medication to Paliperidone Palmitate

PHASE4CompletedINTERVENTIONAL
Enrollment

154

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions
Schizophrenia
Interventions
DRUG

Paliperidone palmitate

Paliperidone palmitate will be administrated in accordance with each product's information. Recommended initial loading doses are 150 mg equivalent on Day 1 and 100 mg equivalent on Day 8, followed by subsequent once-monthly administration with 75 mg equivalent or flexible dose between 25 mg and 150 mg equivalent.

Trial Locations (9)

Unknown

Buchun

Cheonan

Chungcheongbuk-Do

Daegu

Goyang

Gyeonggi-do

Incheon

Seognam-Si, Kyungki-Do

Seoul

All Listed Sponsors
lead

Janssen Korea, Ltd., Korea

INDUSTRY

NCT01682161 - A Comparative Study to Evaluate the Evolution of Medication Satisfaction and Adherence in Patients Unsatisfied With Current Oral Atypical Antipsychotics by Switching Medication to Paliperidone Palmitate | Biotech Hunter | Biotech Hunter